Generation Bio Co. (GBIO) - יתרת חוב לטווח ארוך

Generation Bio Co. (GBIO) generates revenue by creating safe gene correction methods to combat orphan pathologies, receiving payments from pharmaceutical partners for joint research. Current genome editing laboratory capacities are engaged in research, while equipment is being calibrated for the production of trial batches. The integration of AI into bioreactors for drug synthesis optimizes formula screening, with the indicator standing at 0.02. The visualization of financial quotes on GURU.Markets is available below.

For Generation Bio Co. (GBIO), which is developing non-viral gene therapy, long-term liabilities record the aggregate of loans with maturities exceeding one year, reflecting the scale of external financing for R&D cycles. By analyzing the company's long-term debt volume, an investor can assess the stability of the capital structure: a stagnant indicator level without growth in royalty revenue signals operational stagnation and a dependence on borrowed funds.